Condensed Consolidated Statement of Stockholders' Equity (Unaudited) (USD $) - USD ($)	Common Stock [Member]	Additional Paid-In Capital [Member]	Accumulated Deficit	Total
Beginning Balance, Shares at Dec. 31, 2016	37,544,531
Beginning Balance, Amount at Dec. 31, 2016	$ 37,545	$ 55,160,387	$ (45,223,574)	$ 9,974,358
Issuance of common stock associated with the acquisition of Healthspan Research LLC, Shares	367,648
Issuance of common stock associated with the acquisition of Healthspan Research LLC, Amount	$ 367	999,635		1,000,002
Exercise of stock options, Shares	3,202
Exercise of stock options, Amount	$ 3	6,620		6,623
Vested restricted stock, Shares	2,667
Vested restricted stock, Amount	$ 3	(3)		0
Share-based compensation		319,830		319,830
Net loss			(1,928,755)	(1,928,755)
Ending Balance, Shares at Apr. 01, 2017	37,918,048
Ending Balance, Amount at Apr. 01, 2017	$ 37,918	56,486,469	(47,152,329)	9,372,058
Beginning Balance, Shares at Dec. 31, 2016	37,544,531
Beginning Balance, Amount at Dec. 31, 2016	$ 37,545	55,160,387	(45,223,574)	$ 9,974,358
Exercise of stock options, Shares				114,813
Net loss				$ (2,555,802)
Ending Balance, Shares at Sep. 30, 2017	47,650,252
Ending Balance, Amount at Sep. 30, 2017	$ 47,650	81,469,567	(47,779,376)	33,737,841
Beginning Balance, Shares at Apr. 01, 2017	37,918,048
Beginning Balance, Amount at Apr. 01, 2017	$ 37,918	56,486,469	(47,152,329)	9,372,058
Issuance of common stock, net of offering costs, Shares	7,649,968
Issuance of common stock, net of offering costs, Amount	$ 7,650	18,698,634		18,706,284
Exercise of stock options, Shares	1,875
Exercise of stock options, Amount	$ 2	5,342		5,344
Vested restricted stock, Shares	2,000
Vested restricted stock, Amount	$ 2	(2)		0
Share-based compensation		399,861		399,861
Net loss			(2,764,124)	(2,764,124)
Ending Balance, Shares at Jul. 01, 2017	45,571,891
Ending Balance, Amount at Jul. 01, 2017	$ 45,572	75,590,304	(49,916,453)	25,719,423
Issuance of common stock, net of offering costs, Shares	1,965,417
Issuance of common stock, net of offering costs, Amount	$ 1,965	5,005,512		5,007,477
Exercise of stock options, Shares	111,611
Exercise of stock options, Amount	$ 112	382,935		383,047
Vested restricted stock, Shares	1,333
Vested restricted stock, Amount	$ 1	(1)		0
Share-based compensation		490,817		490,817
Net loss			2,137,077	2,137,077
Ending Balance, Shares at Sep. 30, 2017	47,650,252
Ending Balance, Amount at Sep. 30, 2017	$ 47,650	$ 81,469,567	$ (47,779,376)	$ 33,737,841